Altman Peter purchased $4K of BCDA

Altman Peter (President and CEO) purchased 5,000 shares of BioCardia, Inc. (BCDA) at $0.85 on 2026-06-09.

Original reporting
SEC EDGAR · Altman Peter
Published Jun 9, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 10:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BCDA
Bullish
medium confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDABullishLow
01

Why it matters

The only new information is the disclosed open-market purchase details (5,000 shares at $0.85, total $4,250) and post-transaction holdings (298,266 shares). No operational or financial guidance is provided.

02

Market read

Traders may note insider buying as a sentiment input, but the transaction size and lack of fundamental updates make it unlikely to drive a sustained repricing.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still does not disclose intent, timing constraints, or whether the purchase is part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: filed 2026-06-09 (same day as transaction)

Background

This is an SEC Form 4 insider transaction for BioCardia, Inc. (BCDA) by its President and CEO, Altman Peter.

Company-level read

Ticker impact

$BCDABullishMedium confidence
Context

BioCardia CEO Altman Peter filed a Form 4 open-market purchase of 5,000 shares at $0.85 on 2026-06-09.

Expected impact

Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider purchases can be read as confidence, but the disclosed size ($4,250) is modest and the filing provides no new operating, financial, or regulatory information.

Market effects

No clear sector read-through from a small insider open-market purchase.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (e.g., compensation-related liquidity needs) and do not necessarily reflect a change in business outlook.

Key entities

  • BioCardia, Inc.

    Company whose Form 4 insider transaction was filed (BCDA).

  • Altman Peter

    President and CEO who purchased 5,000 shares open-market on 2026-06-09.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BCDAMed

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

$BCDAMedAI 8/10

BioCardia’s CardiAMP Completes Japan Pre-Market Consultation, First Cardiac Cell Therapy to Do So

BioCardia (BCDA) completed Japan's PMDA consultation for its CardiAMP Cell Therapy System, positioning it for a marketing approval application. The therapy, which uses a patient's own bone marrow cells, aims to treat heart damage. BioCardia targets a formal submission by late 2026 and commercial revenue by 2028. The company's Phase 3 trial showed significant improvements in a subgroup of patients with elevated NTproBNP levels, which PMDA has reviewed positively.

$BCDAMed

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application SUNNYVALE, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (NASDAQ: BCDA) , a global le

$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.